Listed

Lifevantage Corp: Form 10-Q for the period ended Dec 31, 2020

Filed with the SEC on Feb 2, 2021 and accepted by EDGAR at Feb 2, 2021, 16:07 ET.

Share

Management's discussion and analysis

As filed, 39,241 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Overview

We are a company focused on biohacking the aging code through nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. We are dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically-validated products and a financially rewarding direct sales opportunity to customers and independent distributors. We engage in the identification, research, development and distribution of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. We currently sell our products to customers and independent distributors in two geographic regions that we have classified as the Americas region and the Asia/Pacific & Europe region.

The success and growth of our business is primarily based on the effectiveness of our independent distributors to attract and retain customers in order to sell our products and our ability to attract and retain independent distributors. When we are successful in attracting and retaining independent distributors and customers, it is largely because of:

  • Our products, including Protandim®, our line of scientifically-validated dietary supplements, LifeVantage® Omega+ and ProBio dietary supplements, TrueScience®, our line of skin and hair care products, Petandim® for Dogs, our companion pet supplement formulated to combat oxidative stress in dogs, Axio®, our nootropic energy drink mixes, and PhysIQ™, our smart weight management system;
  • Our compensation plan and other sales initiatives; and
  • Our delivery of superior customer service.

As a result, it is vital to our success that we leverage our product development resources to develop and introduce compelling and innovative products and provide opportunities for our independent distributors to sell these products in a variety of markets. We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore. We also sell our products in a number of countries to customers for personal consumption only. In addition, we sell our products in China through our cross-border e-commerce business model. Entering a new market requires a considerable amount of time, resources and continued support. If we are unable to properly support an existing or new market, our revenue growth may be negatively impacted.

Impact of COVID-19 on Our Business

The pandemic caused by an outbreak of a new strain of coronavirus (“COVID-19”) has resulted, and is likely to continue to result, in significant national and global economic disruption and may adversely affect our business. Uncertainty exists concerning the magnitude of the impact and duration of the COVID-19 pandemic. As of the date of this filing, we have experienced multiple disruptions at the corporate level as we have transitioned our corporate workforce to a remote working environment, closed some of our showrooms and will call locations in international markets and cancelled multiple planned events in order to comply with group meeting restrictions. Our independent distributors have also experienced disruptions. Specifically, in Japan, independent distributors are required to provide a hard-copy introductory packet (gaiyoshomen) in person to each person they approach to sponsor as an independent distributor before presenting our products and business opportunity. This requirement inhibits distributors from connecting with potential new distributors virtually or through social media. Accordingly, quarantines, avoidance of public places and general concerns about physical distancing related to COVID-19 or otherwise can significantly reduce the ability for independent distributors to meet people in person and commence the enrollment process. Elsewhere, our independent distributors have begun to adapt their approach for customer outreach and enrollment, including transitioning to a stronger social media presence, in an effort to sustain their sales volume. Our business may, in the future, experience additional disruptions and be negatively impacted by the COVID-19 pandemic, including as a result of limitations on the ability of our suppliers to manufacture, or procure from manufacturers, the products we sell or any of the raw materials or components required in the production process, or to meet delivery requirements and commitments; limitations on the ability of our employees to perform their work due to illness caused by the pandemic or local, state, or federal orders requiring employees to remain at home; limitations on the ability of carriers to deliver our products to customers; limitations on the ability of our independent distributors to conduct their businesses and purchase our products; and limitations on the ability of our independent distributors or customers to continue to purchase our products due to decreased disposable income.

We have made modifications, and are evaluating additional potential modifications that may be needed, to protect our supply chain and preserve adequate liquidity to ensure that our business can continue to operate during this uncertain time. Some states have issued executive orders requiring all workers to remain at home, unless their work is critical, essential, or life-sustaining. We have transitioned all of our corporate employees to a work from home model and, to date, our employees are performing well in the new environment. With respect to liquidity, we are evaluating and taking actions to ensure that we continue to responsibly manage expenses across our organization.

While we are unable to determine or predict the nature, duration or scope of the overall impact that the COVID-19 pandemic will have on our business, results of operations, liquidity or capital resources, we will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state or local authorities or that we determine are in the best interests of our employees, independent distributors, customers, and stockholders.

Our Products

Our line of scientifically-validated dietary supplements includes Protandim® NRF1 Synergizer®, Protandim® Nrf2 Synergizer®, Protandim® NAD Synergizer™, LifeVantage® Omega+ and LifeVantage® ProBio. The Protandim® NRF1 Synergizer® is formulated to increase cellular energy and performance by boosting mitochondria production to improve cellular repair and slow cellular aging. The Protandim® Nrf2 Synergizer® contains a proprietary blend of ingredients and has been shown to combat oxidative stress and enhance energy production by increasing the body’s natural antioxidant protection at the genetic level, inducing the production of naturally-occurring protective antioxidant enzymes including superoxide dismutase, catalase, and glutathione synthase. The Protandim® NAD Synergizer™ was specifically formulated to target cell signaling pathways involved in the synthesis and recycling of a specific molecule called NAD (nicotinamide adenine dinucleotide), and has been shown to double sirtuin activity, supporting increased health, focus, energy, mental clarity and mood. LifeVantage® Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. LifeVantage® ProBio is a dietary supplement designed to support optimal digestion and immune system function. Our TrueScience® line of anti-aging skin and hair care products includes TrueScience® Facial Cleanser, TrueScience® Perfecting Lotion, TrueScience® Eye Serum, TrueScience® Anti-Aging Cream, TrueScience® Hand Cream, TrueScience® Invigorating Shampoo, TrueScience® Nourishing

Conditioner and TrueScience® Scalp Serum. Petandim® for Dogs is a supplement specially formulated to combat oxidative stress in dogs through Nrf2 activation. Axio® is our line of nootropic energy drink mixes formulated to promote alertness and support mental performance. PhysIQ™ is our smart weight management system which includes PhysIQ™ Fat Burn, PhysIQ™ Prebiotic and PhysIQ™ Whey Protein, all formulated to aid in weight management.

We sell our products both individually and in stacks. A stack consists of multiple products bundled together that are designed to achieve a specific result. By studying the effects of nutrients and natural compounds, we have developed scientifically-backed nutrigenomics products that promote healthy aging on the cellular level. By stacking these products together, we have created a foundation for biohacking a healthier life. The Vitality Stack™ includes four of our nutrigenomics products — Protandim® NRF1 Synergizer®, Protandim® Nrf2 Synergizer®, LifeVantage® Omega+ and LifeVantage® ProBio. This product stack was designed to provide a foundation for wellness, supporting healthy organs, including the brain, heart, eyes, and other vitals. With the Ultimate Stack™, we added Protandim® NAD Synergizer™ and PhysIQ™ Prebiotic to our Vitality Stack™ to support gut health and increase sirtuin activity, supporting increased health, focus, energy, mental clarity and mood. The Protandim® Tri-Synergizer™ consists of our Protandim® NRF1 Synergizer®, Protandim® Nrf2 Synergizer® and Protandim® NAD Synergizer™, and was designed to effectively reduce oxidative stress, support mitochondria function, increase sirtuin activity, and target cell signaling pathways to fight the effects of aging. We also offer stacks for our PhysIQ™ and TrueScience® product lines.

We currently have additional products in development. Any delays or difficulties in introducing compelling products or attractive initiatives or tools into our markets may have a negative impact on our revenue and our ability to attract new independent distributors and customers.

Accounts

Because we utilize a direct selling model for the distribution of a majority of our products, the success and growth of our business is primarily based on the effectiveness of our independent distributors to attract customers and sell our products and our ability to attract new and retain existing independent distributors. Changes in our product sales typically are the result of variations in product sales volume relating to fluctuations in the number of active independent distributors and customers purchasing our products. The number of active independent distributors and customers is, therefore, used by management as a key non-financial measure.

The following tables summarize the changes in our active accounts base by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated. For purposes of this report, we define “Active Accounts” as only those independent distributors and customers who have purchased from us at any time during the most recent three-month period, either for personal use or for resale.

Active Independent Distributors As of December 31, 2020 2019 Change from Prior Year Percent Change
Americas 45,000 67.2% 46,000 67.6% (1,000) (2.2)%
Asia/Pacific & Europe 22,000 32.8% 22,000 32.4% — —%
Total Active Independent Distributors 67,000 100.0% 68,000 100.0% (1,000) (1.5)%
Active Customers
Americas 82,000 76.6% 89,000 78.1% (7,000) (7.9)%
Asia/Pacific & Europe 25,000 23.4% 25,000 21.9% — —%
Total Active Customers 107,000 100.0% 114,000 100.0% (7,000) (6.1)%
Active Accounts
Americas 127,000 73.0% 135,000 74.2% (8,000) (5.9)%
Asia/Pacific & Europe 47,000 27.0% 47,000 25.8% — —%
Total Active Accounts 174,000 100.0% 182,000 100.0% (8,000) (4.4)%

22

Results of Operations

Three and Six Months Ended December 31, 2020 and 2019

Revenue. We generated net revenue of $59.0 million and $61.2 million during the three months ended December 31, 2020 and 2019, respectively. We generated net revenue of $113.8 million and $117.5 million during the six months ended December 31, 2020 and 2019, respectively. Foreign currency fluctuations positively impacted our revenue $0.7 million or 1.2% and $0.9 million or 0.8% during the three and six months ended December 31, 2020, respectively.

Americas. The following table sets forth revenue for the three and six months ended December 31, 2020 and 2019 for the Americas region (in thousands):

Three Months Ended December 31, 2020 2019 % Change Six Months Ended December 31, 2020 2019 % Change
United States $39,416 $41,355 (4.7)% $75,525 $78,701 (4.0)%
Other 2,467 2,929 (15.8)% 5,034 5,764 (12.7)%
Americas Total $41,883 $44,284 (5.4)% $80,559 $84,465 (4.6)%

Revenue in the Americas region for the three and six months ended December 31, 2020 decreased $2.4 million or 5.4% and $3.9 million or 4.6%, respectively, from the prior year periods. Total Active Accounts decreased by 5.9% in the region compared to the prior year period which drove the decrease in revenues. Additionally, during our October 2019 global convention, we launched our Protandim® NAD Synergizer™ product which generated significant revenues during the prior year periods. The decrease was partially offset due to the launch of new, limited-time only flavors of our Axio® drink mixes during our October 2020 virtual convention, increased average revenue per account as compared to the prior year periods and increased sales associated with various product promotions during our second fiscal quarter.

Asia/Pacific & Europe. The following table sets forth revenue for the three and six months ended December 31, 2020 and 2019 for the Asia/Pacific & Europe region and its principal markets (in thousands):

Three Months Ended December 31, 2020 2019 % Change Six Months Ended December 31, 2020 2019 % Change
Japan $11,120 $10,497 5.9% $21,551 $21,555 —%
Australia & New Zealand 2,481 2,544 (2.5)% 4,984 4,627 7.7%
Greater China 1,413 1,762 (19.8)% 2,297 2,749 (16.4)%
Other 2,110 2,155 (2.1)% 4,444 4,074 9.1%
Asia/Pacific & Europe Total $17,124 $16,958 1.0% $33,276 $33,005 0.8%

Revenue in the Asia/Pacific & Europe region increased $0.2 million or 1.0% and $0.3 million or 0.8% for the three and six months ended December 31, 2020, respectively, as compared to the prior year periods. Active Accounts in the region remained consistent as compared to the prior year period. We continue to see steady year-over-year revenues from Japan, our second largest market, even with severe restrictions in place for in person meeting and recruiting due to the COVID-19 pandemic. We are encouraged by the results we are seeing in our Australia and New Zealand market following the full on the ground launch of New Zealand in November 2019 and a strong second quarter in our Thailand market. These increases were partially offset by continued weakening in our Greater China market in the current year period.

Revenue in the Asia/Pacific & Europe region was positively impacted by foreign currency exchange rate fluctuations in the amount of approximately $0.8 million or 4.5% and $1.1 million or 3.2% during the three and six months ended December 31, 2020, respectively, as compared to the prior year periods. Revenue in Japan was positively impacted by foreign exchange rate fluctuations in the amount of approximately $0.4 million or 4.4% and $0.6 million or 2.6% during the three and six months ended December 31, 2020, respectively, as compared to the prior year periods. On a constant currency basis, revenue in Japan increased 2.4% and decreased 2.2% for the three and six months ended December 31, 2020, respectively, as compared to the prior year periods.

Globally, we continue to focus on strengthening our core business. Our fiscal 2021 initiatives focus on strengthening our subscription services and programs, further supporting and growing our revenues for our Protandim® NAD Synergizer™ product that was launched in October 2019, expanding our global footprint through new market launches and enhancing our product lines in international markets, the roll out of customer referral and loyalty programs, enhancements to our various internal and external systems, and the continued development and improvement of distributor training tools and technologies that will help our independent distributors grow their businesses and improve the customer experience. During the remainder of fiscal 2021 we plan to continue to support our red carpet program, which is designed to attract and retain experienced and proven leaders within our industry, and roll out other programs designed to help our independent distributors build and maintain strong businesses. These activities have been developed and designed to help increase enrollments of new customers and independent distributors, retain new and existing customers and independent distributors, increase average revenue per account and improve our customer and independent distributor experience. We plan on further evaluating and improving our internal systems and business model in order to strengthen and adapt our business to the current and post pandemic environment.

Gross Margin. Our gross profit percentage for the three months ended December 31, 2020 and 2019 was 82.7% and 83.3%, respectively. Our gross profit percentage for the six months ended December 31, 2020 and 2019 was 82.8% and 83.5%, respectively. The decrease in gross margins, as compared to the prior year periods, is primarily due to increased shipping to customer expenses during the current year period, decreased fee revenues as a result of fewer distributor meetings being held during the current year period due to the COVID-19 pandemic, as well as shifts in geographic and product sales mix.

Commissions and Incentives. Commissions and incentives expenses during the three months ended December 31, 2020 were $27.2 million or 46.0% of revenue as compared to commissions and incentives expenses of $29.2 million or 47.7% of revenue for the three months ended December 31, 2019. Commissions and incentives expenses during the six months ended December 31, 2020 were $52.8 million or 46.4% of revenue as compared to commissions and incentives expenses of $56.0 million or 47.7% of revenue for the six months ended December 31, 2019. The decrease in commissions and incentives expenses as a percentage of revenue is due mainly to the timing and magnitude of investments in our promotional and incentive programs and our red carpet program. These programs have been limited due to the COVID-19 pandemic which has restricted our ability to hold promotional and incentive events and activities.

We expect commissions and incentives expenses for the remainder of fiscal 2021, as a percentage of revenue, to fluctuate slightly as we continue to adapt our operating plan to the current business environment and continue to be opportunistic with investments in promotional and incentive programs and our red carpet program to drive revenue growth.

Selling, General and Administrative. Selling, general and administrative expenses during the three months ended December 31, 2020 were $16.2 million or 27.5% of revenue as compared to selling, general and administrative expenses of $18.1 million or 29.6% of revenue for the three months ended December 31, 2019. Selling, general and administrative expenses during the six months ended December 31, 2020 were $32.5 million or 28.6% of revenue as compared to selling, general and administrative expenses of $35.8 million or 30.5% of revenue for the six months ended December 31, 2019. The decrease in selling, general and administrative expenses during the three and six months ended December 31, 2020 compared to the prior year periods is primarily due to decreased event and travel expenses, due to restrictions on group meetings associated with the COVID-19 pandemic, as well as decreased incentive and stock compensation expenses due, in part, to the reversal of unvested stock awards due to departure of executives during the current year periods. These decreases were partially offset by increased executive severance and transition expenses, depreciation expenses associated with our investment in new technology assets that have been placed in service; and increased depreciation in corporate office leasehold improvements due to the exercise of an early termination clause in our current corporate office lease.

We expect selling, general and administrative expenses, as a percent of revenue, to fluctuate during the remainder of the fiscal year as we adapt our operating plan to the COVID-19 business environment, resume some virtual and in-person distributor trainings and events as we are able, leverage current spending and execute on our strategic investments and initiatives designed to increase revenue, and due to the timing of product and market launches and other planned events during the year.

Total Other Expense. During the three and six months ended December 31, 2020, we recognized net other income of $0.1 million and net other expenses of $23,000, respectively, as compared to net other expenses of $0.2 million and $0.3 million, respectively, for the three and six months ended December 31, 2019. Total other expense for the three and six months ended December 31, 2020 and 2019 consisted primarily of foreign currency gains and losses and interest expense.

The following table sets forth interest expense for the three and six months ended December 31, 2020 and 2019 (in thousands):

Contractual interest expense: Three Months Ended December 31, 2020 2019 Six Months Ended December 31, 2020 2019
2016 Term Loan $— $15 $— $37
Amortization of deferred financing fees:
2016 Term Loan — 2 — 4
Amortization of debt discount:
2016 Term Loan — 13 — 26
Other 9 11 15 22
Total interest expense $9 $41 $15 $89

Income Tax Expense. We recognized income tax expense of $1.8 million and $2.7 million, respectively, for the three and six months ended December 31, 2020, as compared to income tax benefit of $0.8 million and $0.2 million, respectively, for the three and six months ended December 31, 2019.

The effective tax rate was 29.8% of pre-tax income during the six months ended December 31, 2020, compared to (2.7)% for the prior year period. The change in the tax rate for fiscal 2021 was mainly due to less favorable tax deductions, relative to pre-tax income, associated with stock awards vesting during the current year, as compared to the prior year period and limitations on deduction of other compensation related items during the current year.

We expect that our effective tax rate will fluctuate slightly during the remainder of fiscal 2021 as the impact of discrete items related to vesting of stock awards and other permanent differences are recognized during the year; however, our tax rate can be significantly impacted by various book to tax differences and fluctuations in our stock price that occur during the year which are difficult to forecast.

Liquidity and Capital Resources

Liquidity

Our primary liquidity and capital resource requirements are to finance the cost of our planned operating expenses and working capital (principally inventory purchases), fund capital expenditures, and service our debt, which includes any outstanding balances under the 2016 Credit Facility. We have generally relied on cash flow from operations to fund operating activities and we have, at times, incurred long-term debt in order to fund stock repurchases and strategic transactions.

As of December 31, 2020, our available liquidity was $19.7 million, which consisted of available cash and cash equivalents. This represents a decrease of $2.4 million from the $22.1 million in cash and cash equivalents as of June 30, 2020.

During the six months ended December 31, 2020, our net cash provided by operating activities was $4.8 million as compared to $5.8 million during the six months ended December 31, 2019.

During the six months ended December 31, 2020, our net cash used in investing activities was $1.5 million, as a result of the purchase of fixed assets. During the six months ended December 31, 2019, our net cash used in investing activities was $1.6 million, as a result of the purchase of fixed assets.

Cash used in financing activities during the six months ended December 31, 2020 was $5.9 million as a result of our repurchase of common stock and shares purchased as payment of tax withholding on vesting of equity awards, partially offset by proceeds from stock issued under our employee stock purchase plan and stock option exercises. Cash used in financing activities during the six months ended December 31, 2019 was $8.4 million as a result of our repurchase of common stock, quarterly principal payments on the 2016 Term Loan and shares purchased as payment of tax withholding on vesting of equity awards, partially offset by proceeds from stock issued under our employee stock purchase plan and stock option exercises.

At December 31, 2020 and June 30, 2020, the total amount of our foreign subsidiary cash was $8.7 million and $6.8 million, respectively. The federal tax reform legislation that was passed into law during December 2017 enacted a 100% dividend deduction for > 10% owned foreign corporations. Therefore, in the future, if needed, we expect to be able to repatriate cash from foreign subsidiaries without paying additional U.S. taxes.

At December 31, 2020, we had working capital (current assets minus current liabilities) of $20.0 million, compared to working capital of $18.8 million at June 30, 2020. We believe that our cash and cash equivalents balances and our ongoing cash flow from operations will be sufficient to satisfy our cash requirements for at least the next 12 months. The majority of our historical expenses have been variable in nature and as such, a potential reduction in the level of revenue would reduce our cash flow needs. In the event that our current cash balances and future cash flow from operations are not sufficient to meet our obligations or strategic needs, we would consider raising additional funds, which may not be available on terms that are acceptable to us, or at all. Our credit facility, however, contains covenants that restrict our ability to raise additional funds in the debt markets and repurchase our equity securities without prior approval from the lender. Additionally, our credit facility, as amended, provides for a revolving loan facility in an aggregate principal amount up to $5.0 million. We would also consider realigning our strategic plans including a reduction in capital spending and expenses.

Capital Resources

Shelf Registration Statement

On March 24, 2020, we filed a shelf registration statement (the "Shelf Registration") on Form S-3 with the SEC that was declared effective April 3, 2020, which permits us to offer up to $75 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time. Our Shelf Registration is intended to provide us with additional flexibility to access capital markets for general corporate purposes, which may include, among other purposes, working capital, capital expenditures, other corporate expenses and acquisitions of assets, licenses, products, technologies or businesses.

2016 Credit Facility

On March 30, 2016, we entered into a Loan Agreement (the “2016 Loan Agreement”) to refinance our outstanding debt. In connection with the 2016 Loan Agreement and on the same date, we entered into a security agreement (the “Security Agreement”). The 2016 Loan Agreement provides for a term loan in an aggregate principal amount of $10.0 million (the “2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed $2.0 million (the “2016 Revolving Loan,” and collectively with the 2016 Term Loan, the 2016 Loan Agreement and the Security Agreement, the “2016 Credit Facility”).

The principal amount of the 2016 Term Loan was payable in consecutive quarterly installments in the amount of $0.5 million plus accrued interest beginning with the fiscal quarter ended June 30, 2016. If we borrow under the 2016 Revolving Loan, interest will be payable quarterly in arrears on the last day of each fiscal quarter.

On May 4, 2018, we entered into a loan modification agreement, which amended the 2016 Credit Facility (“Amendment No. 1”). Amendment No. 1 revised the maturity date from March 30, 2019 to March 31, 2021 (the “Maturity Date”) and increased the fixed interest rate for the term loan from 4.93% to 5.68%. Amendment No. 1 also revised certain financial covenants. The minimum fixed charge coverage ratio (as defined in Amendment No. 1) was revised from a minimum of 1.50 to 1.00 to 1.25 to 1.00, measured on a trailing twelve-month basis, at the end of each fiscal quarter. The minimum working capital was increased from $5.0 million to $8.0 million. The funded debt to EBITDA ratio was replaced with the total liabilities to tangible net worth ratio (as defined in Amendment No. 1) of not greater than 3.00 to 1.00 at the end of each quarter. The minimum tangible net worth measure was removed from the financial covenants.

On February 1, 2019, we entered into a loan modification agreement, which amended the 2016 Credit Facility ("Amendment No. 2"). Under Amendment No. 2, we made a principal payment of $2.0 million and increased the revolving loan facility from $2.0 million to $5.0 million. Amendment No. 2 also revised certain financial covenants. The minimum fixed charge coverage ratio (as defined in Amendment No. 2) was revised from a minimum of 1.25 to 1.00 to 1.10 to 1.00, measured on a trailing twelve-month basis, at the end of each fiscal quarter. The minimum working capital was decreased from $8.0 million to $6.0 million.

The 2016 Credit Facility, as amended, contains customary covenants, including affirmative and negative covenants that, among other things, restrict our ability to create certain types of liens, incur additional indebtedness, declare or pay dividends on or redeem capital stock, make other payments to holders of our equity interests, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, sell assets or enter into consolidations, mergers or transfers of all or any substantial part of our assets. As of December 31, 2020, we were in compliance with all applicable non-financial and restrictive covenants under the 2016 Credit Facility, as amended.

The 2016 Credit Facility, as amended, also contains various financial covenants that require us to maintain certain consolidated working capital amounts, total liabilities to tangible net worth ratios and fixed charge coverage ratios. Specifically, we must:

  • Maintain a minimum fixed charge coverage ratio (as defined in the 2016 Loan Agreement, as amended) of at least 1.10 to 1.00 at the end of each fiscal quarter, measured on a trailing twelve month basis;
  • Maintain minimum consolidated working capital (as defined in the 2016 Loan Agreement, as amended) at the end of each fiscal quarter of at least $6.0 million; and
  • Maintain a ratio of total liabilities to tangible net worth (as defined in the 2016 Loan Agreement, as amended) of not greater than 3.00 to 1.00 at the end of each quarter, measured on a trailing twelve month basis.

As of December 31, 2020, we were in compliance with all applicable financial covenants under the 2016 Credit Facility, as amended. Additionally, management anticipates that in the normal course of operations we will be in compliance with the financial covenants during the ensuing year.

During the three months ended March 31, 2020, we repaid, in full, the remaining balance of the 2016 Term Loan in accordance with the terms of the 2016 Credit Facility, as amended.

Commitments and Obligations

The following table summarizes our contractual payment obligations and commitments as of December 31, 2020 (in thousands):

Contractual Obligations Total Payments due by period Less than 1 year 1-3 years 3-5 years Thereafter
Operating lease obligations (1) $21,800 $2,258 $5,687 $3,212 $10,643
Other operating obligations (2) 17,015 10,789 6,226 — —
Total $38,815 $13,047 $11,913 $3,212 $10,643

(1) Operating lease obligations include current and future obligations associated with corporate office leases.

(2) Other operating obligations represent contractual obligations primarily related to marketing and sponsorship commitments and purchases of inventory.

Off-Balance Sheet Arrangements

As of December 31, 2020, we did not have any off-balance sheet arrangements.

Critical Accounting Policies

We prepare our financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we are required to make certain estimates, judgments, and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the periods presented. Actual results could differ from these estimates. Our significant accounting policies are described in Note 2 to our unaudited condensed consolidated financial statements. Certain of these significant accounting policies require us to make difficult, subjective, or complex judgments or estimates. We consider an accounting estimate to be critical if (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

There are other items within our financial statements that require estimation, but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements. Management has discussed the development and selection of these critical accounting estimates with our board of directors, and the audit committee has reviewed the disclosures noted below.

Allowances for Product Returns

We record allowances for product returns at the time we ship the product based on estimated return rates. Subject to some exceptions based on local regulations, our return policy is to provide a full refund for product returned within 30 days. After 30 days of purchase, only unopened product that is in a resalable and restockable condition may be returned within twelve months of purchase and shall receive a 100% refund, less a 10% handling and restocking fee and any shipping and handling costs. As of December 31, 2020, our shipments of products sold totaling approximately $19.2 million were subject to the return policy.

We monitor our product returns estimate on an ongoing basis and revise the allowances to reflect our experience. Our allowance for product returns was $0.2 million at December 31, 2020, compared with $0.3 million at June 30, 2020. To date, product expiration dates have not played any role in product returns, and we do not expect that they will in the future as it is unlikely that we will ship product with an expiration date earlier than the latest allowable product return date.

Inventory Valuation

We value our inventory at the lower of cost or net realizable value on a first-in first-out basis. Accordingly, we reduce our inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability equal to the difference between the cost of the inventory and its net realizable value. Factors utilized in the determination of net realizable value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new production introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

During the three months ended December 31, 2020 and 2019, we recognized expenses of approximately $45,000 and $0.1 million, respectively, related to obsolete and slow-moving inventory. During the six months ended December 31, 2020 and 2019, we recognized expenses of $0.1 million and $0.2 million, respectively, related to obsolete and slow-moving inventory.

Revenue Recognition

Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales, value add, and other taxes that we collect concurrent with revenue-producing activities are excluded from revenue.

Stock-Based Compensation

We use the fair value approach to account for stock-based compensation in accordance with current accounting guidance. We recognize compensation costs for awards with performance conditions when we conclude it is probable that the performance conditions will be achieved. We reassess the probability of vesting at each balance sheet date and adjust compensation costs based on our probability assessment. For awards with market-based performance conditions, the cost of the awards is recognized as the requisite service is rendered by the employees, regardless of when, if ever, the market-based performance conditions are satisfied.

Research and Development Costs

We expense all of our payments related to research and development activities as incurred.

Legal Accruals

We are occasionally involved in lawsuits and disputes arising in the normal course of business. Management regularly reviews all pending litigation matters in which we are involved and establishes accruals as we deem appropriate for these litigation matters when a probable loss estimate can be made. Estimated accruals require management judgment about future events. The results of lawsuits are inherently unpredictable and unfavorable resolutions could occur. As such, the amount of loss may differ from management estimates.

Recently Issued Accounting Standards

See Note 2 to our unaudited condensed consolidated financial statements for a discussion of recently issued accounting standards.

Market risk

As filed, 2,576 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We conduct business in several countries and intend to continue to grow our international operations. Net revenue, operating income and net income are affected by fluctuations in currency exchange rates and other uncertainties in doing business and selling products in more than one currency. In addition, our operations are exposed to risks associated with changes in social, political and economic conditions inherent in international operations, including changes in the laws and policies that govern international investment in countries where we have operations, as well as, to a lesser extent, changes in U.S. laws and regulations relating to international trade and investment.

Foreign Currency Risk

During the six months ended December 31, 2020, approximately 34% of our net revenue was realized outside of the United States. The local currency of each international subsidiary is generally the functional currency. All revenue and expenses are translated at weighted-average exchange rates for the periods reported. Therefore, our reported revenue and earnings will be positively impacted by a weakening of the U.S. dollar and will be negatively impacted by a strengthening of the U.S. dollar. Currency fluctuations, however, have the opposite effect on our expenses incurred outside the United States. Given the large portion of our business derived from Japan, any weakening of the Japanese yen will negatively impact our reported revenue and profits, whereas a strengthening of the Japanese yen will positively impact our reported revenue and profits. Because of the uncertainty of exchange rate fluctuations, it is difficult to predict the effect of these fluctuations on our future business, product pricing and results of operations or financial condition. Changes in various currency exchange rates affect the relative prices at which we sell our products. We regularly monitor our foreign currency risks and periodically take measures to reduce the risk of foreign exchange rate fluctuations on our operating results. Additionally, we may seek to reduce our exposure to fluctuations in foreign currency exchange rates through the use of foreign currency exchange contracts. We do not use derivative financial instruments for trading or speculative purposes. At December 31, 2020, we did not have any derivative instruments. A 10% strengthening of the U.S. dollar compared to all of the foreign currencies in which we transact business would have resulted in a 3.1% decrease of our six months ended December 31, 2020 revenue, in the amount of $3.5 million.

Controls and procedures

As filed, 2,824 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act of 1934, as amended) that are designed to ensure that the information required to be disclosed in the reports we file or submit under the Exchange Act of 1934, as amended, is (a) recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and (b) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of the end of the period covered by this quarterly report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness and design and operation of such disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were designed and operating effectively as of December 31, 2020.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the quarter ended December 31, 2020 that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

An evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 of the Exchange Act of 1934, as amended, was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter. That evaluation did not identify any changes in our internal control over financial reporting during the three months ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations of Internal Control Over Financial Reporting

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Risk factors

As filed, 688 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in “Part I. Item 1A — Risk Factors” in our annual report on Form 10-K for the fiscal year ended June 30, 2020, filed on August 18, 2020. The risks and uncertainties described in such risk factors and elsewhere in this report have the potential to materially affect our business, financial condition, results of operations, cash flows, projected results and future prospects. We do not believe that there have been any material changes to the risk factors previously disclosed in our recent SEC filings, including our most recently filed Form 10-K, as referenced above.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-10-01 to 2020-12-31$59.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2020-07-01 to 2020-12-31$113.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-10-01 to 2020-12-31$10.2mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2020-07-01 to 2020-12-31$19.6mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-10-01 to 2020-12-31$48.8mus-gaap:GrossProfit
Gross profit6 months2020-07-01 to 2020-12-31$94.2mus-gaap:GrossProfit
Research and development3 months2020-10-01 to 2020-12-31$200.0kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2020-07-01 to 2020-12-31$400.0kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-10-01 to 2020-12-31$16.2mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2020-07-01 to 2020-12-31$32.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-10-01 to 2020-12-31$5.4mus-gaap:OperatingIncomeLoss
Operating income6 months2020-07-01 to 2020-12-31$8.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-10-01 to 2020-12-31$9.0kus-gaap:InterestExpense
Interest expense6 months2020-07-01 to 2020-12-31$15.0kus-gaap:InterestExpense
Income tax3 months2020-10-01 to 2020-12-31$1.8mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2020-07-01 to 2020-12-31$2.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-10-01 to 2020-12-31$3.8mus-gaap:NetIncomeLoss
Net income6 months2020-07-01 to 2020-12-31$6.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-10-01 to 2020-12-31$0.26us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2020-07-01 to 2020-12-31$0.43us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-10-01 to 2020-12-31$0.27us-gaap:EarningsPerShareBasic
Basic EPS6 months2020-07-01 to 2020-12-31$0.44us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-10-01 to 2020-12-3114,439,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2020-07-01 to 2020-12-3114,547,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2020-07-01 to 2020-12-31$4.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2020-07-01 to 2020-12-31$1.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases6 months2020-07-01 to 2020-12-31$6.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Current assetsAt period end2020-12-31$42.5mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$74.4mus-gaap:Assets
Current liabilitiesAt period end2020-12-31$22.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-12-31$38.9mus-gaap:Liabilities
Shareholders' equityAt period end2020-12-31$35.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000849146-21-000031. Last ingested by Listed: Nov 13, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.